Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

When it came to innovations in biotech, there was a clear winner: lenacapavir, a drug that was found to prevent HIV infections in 100% of the women and girls who received it in a clinical trial.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...